Drug price history · CMS NADAC read 11 November 2026

What have pharmacies paid for Spinosad since 2013?

What pharmacies pay, not what you pay. Spinosad has 1 product in the CMS NADAC survey, 1 product with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged. Spinosad 0.9% Topical Susp: $1.53 per unit at the 2013 survey and $2.01 at 2026 (+32%, thin).
Not medical or financial advice. This page reports what pharmacies pay to acquire a drug, from the CMS NADAC survey. It is not what you will be charged, and it says nothing about which medicine is right for you. Ask your pharmacist or prescriber.
Spinosad1 product in NADAC
1product with a price history
  1. Spinosad has 1 product in the CMS NADAC survey, 1 product with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged.
  2. 1 of the changes rest on fewer than 3 priced NDCs at one end and are marked thin: a median over one or two NDCs reflects which NDCs were priced as much as a price movement.
  3. This is a per-unit acquisition cost, not a retail price, a copay or an insurer's price, and it says nothing about why a price moved.

Spinosad 0.9% Topical Susp

Generic

$1.53 per mL at the 2013 year-end survey (1 NDC) and $2.01 at the 2026 survey (3 NDCs): +32%, a thin comparison.

$0$2.012013: median $1.53 per mL, 1 NDC priced2014: median $1.64 per mL, 2 NDCs priced2015: median $1.63 per mL, 2 NDCs priced2016: median $1.81 per mL, 2 NDCs priced2017: median $1.60 per mL, 1 NDC priced2025: median $1.88 per mL, 2 NDCs priced2026: median $2.01 per mL, 3 NDCs priced2013201420152016201720252026
year-end median across the NDCs pricedlowest to highest NDC
Year-end surveyMedian per mLLowest to highestNDCs priced
2013 (2013-12-25)$1.531
2014 (2014-12-31)$1.642
2015 (2015-12-30)$1.632
2016 (2016-12-28)$1.812
2017 (2017-12-27)$1.601
2025 (2025-12-31)$1.882
2026 (2026-11-11)$2.013

CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.

How many companies make Spinosad?

The FDA Orange Book lists no generic maker as marketed for Spinosad. The acquisition costs above are what pharmacies pay across the NDCs priced; the Orange Book count is a separate record and this page does not say that more makers lowered a price. See each maker and the patents still listed on OmniRx.

Where can you go from this record?

Open it in the check to search another drug, or see the CMS pharmacy pricing page for what NADAC measures. For who makes the generic and which patents are listed, see the generic competition check for Spinosad on OmniRx. To check whether a drug is in shortage, see the FDA drug shortages page.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page, year-end surveys 2013 to 2026 (latest 11 November 2026).